Trials / Completed
CompletedNCT05419869
Pilot Decentralized Trial
An Open-Label Study of ALTO-100 in Adults With Major Depressive Disorder (MDD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Alto Neuroscience · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-100.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALTO-100 PO Tablet | Two tablets daily |
Timeline
- Start date
- 2022-06-01
- Primary completion
- 2023-01-13
- Completion
- 2023-01-26
- First posted
- 2022-06-15
- Last updated
- 2024-01-18
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05419869. Inclusion in this directory is not an endorsement.